Skip to content
Wenlo
Sign in
← Markets

Bolt Biotherapeutics, Inc.

Coastlands Capital LP (10% owner) reports BOLT insider transactions

3BOLTFiled Nov 6, 2026, 1:21 PM ET· Period Nov 6, 2026

About this filing

Bolt Biotherapeutics, Inc. (BOLT) filed Form 3 (initial insider holdings) with the SEC on Nov 6, 2026.

View original filing on SEC.gov (opens SEC EDGAR)

Key facts

Insider
Coastlands Capital LP · 10% owner

No transactions reported; holdings only.

Footnotes
  1. F1 Coastlands Capital LP ("Coastlands") and Coastlands Capital GP LLC (the "General Partner") are the investment adviser and general partner, respectively, of Coastlands Capital Partners LP (the "Partnership"). Coastlands Capital LLC ("Coastlands GP") is the general partner of Coastlands. Matthew Perry is the control person of Coastlands, the Partnership, Coastlands GP and the General Partner. The reporting persons are filing this Form 3 jointly, but not as members of a group, and each disclaims membership in a group. Each reporting person also disclaims beneficial ownership of common stock except to the extent of that person's pecuniary interest therein.
  2. F2 Following stockholder approval of the conversion of Series D Non-Voting Convertible Preferred Stock, par value $0.00001 per share ("Series D Preferred Stock"), into shares of Common Stock and, to the extent deemed necessary or advisable, an increase in the number of authorized shares of Common Stock, each share of Series D Preferred Stock will automatically convert into 1,000 shares of Common Stock, subject to certain limitations. The Series D Preferred Stock has no expiration date. Coastlands may not convert such shares if Coastlands, together with its affiliates, would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such conversion.
  3. F3 The warrants to purchase shares of the Issuer's common stock (the "Warrants") become exercisable following the automatic conversion of the Series D Preferred Stock into Common Stock upon receipt of the requisite stockholder approval, and expire on the earlier of (i) 30 days following the Issuer's first public disclosure of top-line results from the first-in-human clinical data from its Program 2 Phase 1 (IL-31 bispecific) and (ii) June 30, 2028. Coastlands may not exercise the Warrants if Coastlands, together with its affiliates, would beneficially own more than 4.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise.

Remarks: Exhibit 99.1 - Agreement Regarding Joint Filing of Statement

More BOLT filings

Not investment advice. Summaries can contain errors; the SEC filing is the official record.